Clinical trial
A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome
NCT03303313 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome
- Lead sponsor
- Alnylam Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- September 19, 2017
- Completion date
- September 12, 2018
- Enrollment
- 0 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.